COMP <GO>
MANE vs MIRM // RSI-14 & 200D SMA MOMENTUM
Veradermics Incorporated (NYSE) VS. Mirum Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MANE 6
— MIRM 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MANE
LAST: $129.53 (-7.27%) • MKT CAP: $5.84B
rsi-technicals
60.4
LAST: $85.74 (+0.87%) • MKT CAP: $5.52B
rsi-technicals
48.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MANE VS. MIRM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MANE | MIRM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.90% | -3.90% | -8.00 | MIRM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.19% | 0.98% | -2.17 | MIRM | /fcf-yield <GO> |
| Operating Margin | -4.30% | -4.20% | -0.10 | MIRM | /operating-margins <GO> |
| Net Profit Margin | -4.20% | -4.50% | +0.30 | MANE | /net-margins <GO> |
| Revenue Growth (YoY) | 4.40% | 54.70% | -50.30 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.29 | +19.71 | MANE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | MIRM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 60.4 | 48.4 | +12.00 | MANE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.99 | +0.08 | MANE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 32.0x | -8.00 | MANE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.84B | $5.52B | $317.0M | MANE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MANE REV | MIRM REV | MANE GROSS % | MIRM GROSS % | MANE FCF | MIRM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $202.6M | $521.3M | — | — | -$71.6M | $54.9M |
| FY 2024 | $75.0M | $336.9M | — | — | -$23.7M | $9.3M |
| FY 2023 | — | $186.4M | — | — | — | -$79.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MANE // BETA 1.07
MIRM // BETA 0.99